Bio-Techne Corporation (NASDAQ:TECH) is one of the most profitable biotech stocks to invest in now. On July 9, TD Cowen analyst Daniel Brennan initiated a new Buy rating on Bio-Techne Corporation (NASDAQ:TECH) with a $65 price target.\nThe analyst told investors that Bio-Techne Corporation (NASDAQ:TECH) has potential for margin expansion and strong organic growth, and believes that the company’s current valuation is undervalued and fails to accurately show its robust growth opportunities in high-demand areas of life science tools.\nBrennan added that despite the macroeconomic risks affecting the company, Bio-Techne Corporation (NASDAQ:TECH) has a solid portfolio that is primarily focused on consumables and is highly regarded by customers, positioning it well to outperform its peers.\nHe thus believes that the consensus growth targets for FY26 are reasonable, particularly following a year of downward revisions. The analyst also expects margin recovery with the scaling of mergers and acquisitions and improvement in market conditions.\nBio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that provides innovative tools and bioactive reagents for the research and clinical diagnostic communities. Its operations are divided into the Protein Sciences, and Diagnostics and Genomics segments.\nThe Protein Sciences segment is involved in the manufacture and development of purified proteins and reagent solutions, while the Diagnostics and Genomics segment develops and manufactures diagnostic products.

10 Most Profitable Biotech Stocks to Invest in Now

Bio-Techne Corporation (NASDAQ:TECH) is highlighted as a profitable biotech stock with a new Buy rating and $65 price target from TD Cowen analyst Daniel Brennan. The analyst cites potential for margin expansion, strong organic growth, and undervalued valuation, while noting the company's focus on consumables and global life sciences operations.